Cancer

Chemotherapy Medications Available in Australia

Chemotherapy remains one of the most widely used cancer treatments in Australia. These powerful medications work by targeting and destroying rapidly dividing cancer cells throughout the body. Australian pharmacies stock numerous chemotherapy agents prescribed by qualified oncologists.

Common chemotherapy medications available include:

• Paclitaxel – used for breast, ovarian, and lung cancers
• Docetaxel – effective against breast and prostate cancers
• Fluorouracil (5-FU) – a foundational drug for colorectal and gastric cancers
• Gemcitabine – used for pancreatic and bladder cancers
• Doxorubicin – a cornerstone agent for various solid tumours and leukaemias
• Cisplatin and carboplatin – platinum-based drugs for ovarian, testicular, and lung cancers
• Methotrexate – serves multiple purposes in cancer treatment

These medications are administered through various routes including intravenous infusion, oral tablets, or injections, depending on the specific drug and treatment protocol. Patients receiving chemotherapy require regular monitoring and supportive care to manage side effects effectively.

Targeted Therapy and Biological Agents

Targeted therapies represent a significant advancement in cancer treatment, working by attacking specific molecular characteristics of cancer cells. These medications are designed to interfere with specific proteins or genes that drive cancer growth, offering potentially fewer side effects than traditional chemotherapy.

Targeted agents available in Australia include trastuzumab (Herceptin) for HER2-positive breast cancers, which blocks growth signals and has dramatically improved outcomes for eligible patients. Bevacizumab (Avastin) inhibits blood vessel formation needed for tumour growth, used across multiple cancer types. Imatinib (Glivec) revolutionised chronic myeloid leukaemia treatment by targeting the BCR-ABL protein. Gefitinib and erlotinib target epidermal growth factor receptors in lung cancers. Sunitinib (Sutent) and sorafenib (Nexavar) are tyrosine kinase inhibitors used for renal cell carcinoma and hepatocellular carcinoma.

Newer agents include crizotinib for ALK-positive lung cancers and venetoclax for chronic lymphocytic leukaemia. These precision medicines require genetic testing to identify suitable patients, ensuring treatment is targeted to those most likely to benefit.

Hormone Therapies and Supportive Medications

Hormone-responsive cancers, particularly breast and prostate cancers, benefit from hormone-blocking therapies. These medications either reduce hormone production or block hormone receptors on cancer cells, slowing or stopping growth.

Tamoxifen remains widely used for oestrogen receptor-positive breast cancer in pre- and postmenopausal women. Aromatase inhibitors including letrozole, anastrozole, and exemestane reduce oestrogen levels in postmenopausal women. Fulvestrant works as an oestrogen receptor degrader for advanced breast cancer. For prostate cancer, medications like bicalutamide and enzalutamide block androgen receptors, while leuprorelin reduces testosterone production.

Supportive medications are equally important in cancer care. Anti-nausea medications including ondansetron and granisetron manage chemotherapy-related nausea. Dexamethasone reduces inflammation and side effects. Filgrastim supports white blood cell recovery after chemotherapy. Bisphosphonates like zoledonic acid protect bone health in patients at risk of bone metastases. Psychotropic medications address anxiety and depression, common in cancer patients.

Immunotherapy and Modern Treatment Advances

Immunotherapy represents a revolutionary approach to cancer treatment, harnessing the body’s immune system to recognise and destroy cancer cells. These innovative medications have transformed outcomes for numerous cancer types and continue expanding across additional indications.

Checkpoint inhibitors are leading immunotherapy agents available in Australia. Pembrolizumab (Keytruda) blocks PD-1 receptors, enabling immune cells to attack cancer cells, used for melanoma, lung cancer, and several other malignancies. Nivolumab (Opdivo) works similarly and is approved for melanoma, renal cell carcinoma, and lung cancer. Atezolizumab targets PD-L1, approved for bladder and non-small cell lung cancers. Durvalumab (Imfinzi) is used in lung cancer treatment.

CAR-T cell therapies represent another frontier, where a patient’s own immune cells are genetically modified to attack leukaemia and lymphoma cells. Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are available through specialist centres in Australia.

These immunotherapies can produce remarkable responses but require careful monitoring for immune-related adverse events. Combination approaches using immunotherapy with chemotherapy or targeted therapy are increasingly standard practice.

Managing Side Effects and Supportive Care

Cancer treatment can produce significant side effects affecting quality of life. Comprehensive supportive care strategies help patients tolerate treatment and maintain wellbeing throughout their cancer journey.

Bone marrow suppression from chemotherapy increases infection, anaemia, and bleeding risks. Supportive medications including growth factors, transfusions, and antibiotics manage these complications. Neuropathy affecting hands and feet responds to gabapentin or pregabalin. Mouth sores (mucositis) are managed with topical treatments and antimicrobials. Constipation from pain medications or chemotherapy requires stool softeners and laxatives. Fatigue, the most common side effect, may improve with exercise, nutrition support, and psychological interventions.

Nutritional support is crucial, with dietitians helping patients maintain adequate intake despite appetite changes. Sleep disturbances respond to sleep hygiene measures and occasionally short-term sleeping aids. Lymphoedema management involves physiotherapy and compression garments. Psychosocial support including counselling, support groups, and peer support significantly improves mental health outcomes.

Hair loss, whilst temporary, profoundly affects body image. Scalp cooling systems can minimise hair loss during certain chemotherapy treatments. Skin care protocols prevent chemotherapy-related dermatological complications. Regular monitoring of blood counts, liver and kidney function ensures treatment remains safe and effective throughout the cancer journey.